Clinical trials: Stage II Prostate Adenocarcinoma
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Prostate Cancer
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00309894
- Testing
- sargramostim, ketoconazole, therapeutic hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Prostate Cancer
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy.
- Trial name
- NCT00003256
- Testing
- alvocidib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation…
- Trial name
- NCT00003104
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Prostate Cancer
Selenium in Treating Patients With Prostate Cancer
RATIONALE: Selenium may prevent or slow the growth of prostate cancer. PURPOSE: This randomized phase II trial is studying how well selenium works in treating patients with prostate cancer.
- Trial name
- NCT00752739
- Testing
- selenium
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Arizona
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00258466
- Testing
- radiation therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance.
- Trial name
- NCT02326805
- Testing
- Laboratory Biomarker Analysis, Rilimogene Galvacirepvec
- Where
- 7 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.
- Trial name
- NCT00052481
- Testing
- quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer
RATIONALE: Learning about changes in DNA over time in patients with prostate cancer undergoing diet and lifestyle changes may help doctors learn about the long-term effects of these changes on disease progression.
- Trial name
- NCT00739791
- Testing
- exercise intervention, gene expression analysis, polymerase chain reaction
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03368547
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Prostatic Diseases, Genital Neoplasms, Male
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.
- Conditions
- Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT00672009
- Testing
- Ixabepilone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center